Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
Key facts
- Who runs it
- Resistell AG
- Where
- Austria, Spain, and Switzerland3 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 246 people enrolled
- Started
- 18 Jan 2023
- Ended
- 5 Sept 2024
- Type of study
- Observational
- Treatments tested
- Resistell Phenotech
- Record updated
- 26 October 2024
- Why it stopped
- Statistical power for primary endpoint (sensitivity) for E. coli and K. pneumoniae and ceftriaxone was achieved
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients who have signed a General Consent form approving use of their residual blood samples for research purposes (applicable at CHUV only)
- Patients who have signed a consent allowing the use of their residual sample (Restprobenerklärung) (applicable at MUI, only)
- Patients over the age of 18 years (>18)
- Patients with bacteremia considered to be due to E. coli or K. pneumoniae
- Patients whose positive blood cultures were not older than 24 hours at the time of AST start
Who cannot take part
- Patients with documented refusal of the use of biological material for research purposes (applicable at CHUV, only)
- Patients with polymicrobial bacteremia
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K. pneumoniae) to clinically relevant antibiotics. The study is designed as a prospective, non-interventional, multi-center, single-arm study.
Read full original descriptionShow less
The blood culture samples from bacteremia patients that are positive for E. coli or K. pneumoniae will be tested with the Resistell Phenotech device after strain identification by MALDI-TOF. The results of the Resistell AST will be compared with the results from the disk diffusion tests (all sites use the Kirby-Bauer disk diffusion test), and site dependent tests (VITEK® 2, BD Phoenix™, MicroScan WalkAway system, and/or EUCAST RAST), which are currently the standard AST methods in the microbiology laboratories at the participating sites.
Treatments tested
- Resistell Phenotech
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia: a Prospective, Non-interventional, Multi-centric, Clinical Performance Study
- Record updated
- 26 October 2024